Kaley T, et al. - Researchers conducted the VE-BASKET study (an open-label, nonrandomized, multicohort study) to determine the activity of vemurafenib, a selective inhibitor of BRAF^V600, in patients with gliomas that harbor this mutation. Patients with BRAF^V600-mutant glioma continuously received vemurafenib 960 mg twice a day until progression, withdrawal or intolerable adverse effects of the disease. Vemurafenib showed evidence of durable antitumor activity in some patients with BRAF^V600-mutant gliomas, although efficacy by histologic subtype appeared to vary qualitatively.